[{"orgOrder":0,"company":"Joint Child Health Project, Mauritius","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"MAURITIUS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Joint Child Health Project, Mauritius","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Joint Child Health Project, Mauritius \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Joint Child Health Project, Mauritius \/ Undisclosed"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"KU Leuven | VISTA-Life | Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ KU Leuven | VISTA-Life | Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ KU Leuven | VISTA-Life | Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nordlandssykehuset HF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Nordlandssykehuset HF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordlandssykehuset HF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"10","companyTruncated":"Nordlandssykehuset HF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"BASF | Pre Diagnostics AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ BASF | Pre Diagnostics AS","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ BASF | Pre Diagnostics AS"},{"orgOrder":0,"company":"Instituto Palacios","sponsor":"Ferrer Internacional","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Instituto Palacios","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Palacios \/ Ferrer Internacional","highestDevelopmentStatusID":"11","companyTruncated":"Instituto Palacios \/ Ferrer Internacional"},{"orgOrder":0,"company":"Universidad Cat\u00f3lica San Antonio de Murcia","sponsor":"Evonik Operations GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Universidad Cat\u00f3lica San Antonio de Murcia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Cat\u00f3lica San Antonio de Murcia \/ Evonik Operations GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Universidad Cat\u00f3lica San Antonio de Murcia \/ Evonik Operations GmbH"},{"orgOrder":0,"company":"Aston University","sponsor":"TearLab Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Aston University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aston University \/ TearLab Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Aston University \/ TearLab Corporation"},{"orgOrder":0,"company":"Northumbria University","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Northumbria University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northumbria University \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"Northumbria University \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ Nutrasource"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Nuvothera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Licensing Agreement","leadProduct":"Omega-3","moa":"||PPA-gamma receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DS Biopharma \/ Nuvothera","highestDevelopmentStatusID":"15","companyTruncated":"DS Biopharma \/ Nuvothera"},{"orgOrder":0,"company":"Eye and Vision Technologies and Research Institute","sponsor":"ZeaVision, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Eye and Vision Technologies and Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eye and Vision Technologies and Research Institute \/ ZeaVision, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Eye and Vision Technologies and Research Institute \/ ZeaVision, Inc."},{"orgOrder":0,"company":"Canadian College of Naturopathic Medicine","sponsor":"McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canadian College of Naturopathic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Canadian College of Naturopathic Medicine \/ McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs","highestDevelopmentStatusID":"8","companyTruncated":"Canadian College of Naturopathic Medicine \/ McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs"},{"orgOrder":0,"company":"Universit\u00e9 de Montr\u00e9al","sponsor":"Neptune Technologies and Bioressources Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Universit\u00e9 de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Universit\u00e9 de Montr\u00e9al \/ Neptune Technologies and Bioressources Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 de Montr\u00e9al \/ Neptune Technologies and Bioressources Inc."},{"orgOrder":0,"company":"McMaster University","sponsor":"Neptune","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oil","sponsorNew":"McMaster University \/ Neptune","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Neptune"},{"orgOrder":0,"company":"Nature's Way Canada","sponsor":"Centre for Contact Lens Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Nature's Way Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nature's Way Canada \/ Centre for Contact Lens Research","highestDevelopmentStatusID":"1","companyTruncated":"Nature's Way Canada \/ Centre for Contact Lens Research"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Samuel Fortin, SFC pharma and associate professor UQAR","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Samuel Fortin, SFC pharma and associate professor UQAR","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Samuel Fortin, SFC pharma and associate professor UQAR"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Physician Recommended Nutriceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Physician Recommended Nutriceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Physician Recommended Nutriceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Physician Recommended Nutriceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Physician Recommended Nutriceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Physician Recommended Nutriceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Physician Recommended Nutriceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Physician Recommended Nutriceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health | Nordic Naturals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fred Hutchinson Cancer Center \/ National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health | Nordic Naturals","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutchinson Cancer Center \/ National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health | Nordic Naturals"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Center for Advancing Translational Sciences | National Institute of Diabetes and Digestive and Kidney Diseases | Building Interdisciplinary Research Careers in Women's Health","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Center for Advancing Translational Sciences | National Institute of Diabetes and Digestive and Kidney Diseases | Building Interdisciplinary Research Careers in Women's Health","highestDevelopmentStatusID":"10","companyTruncated":"Mayo Clinic \/ National Center for Advancing Translational Sciences | National Institute of Diabetes and Digestive and Kidney Diseases | Building Interdisciplinary Research Careers in Women's Health"},{"orgOrder":0,"company":"Per Kogner","sponsor":"Smartfish AS","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Per Kogner","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Per Kogner \/ Smartfish AS","highestDevelopmentStatusID":"6","companyTruncated":"Per Kogner \/ Smartfish AS"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"NORWAY","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Omega-3","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ Undisclosed"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Omega-3","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Omega-3 fatty acids

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hofseth Biocare ASA

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Hofseth Biocare ASA

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Salmon oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Supplementation in Healthy Adults.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 30, 2025

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Hofseth Biocare ASA

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Hofseth Biocare ASA

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Salmon oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 10, 2025

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Sleep

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Canadian College of Naturopathic Medicine

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Canadian College of Naturopathic Medicine

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Generalized Anxiety Disorder.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          October 10, 2022

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Universidad Católica San Antonio de Murcia

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Universidad Católica San Antonio de Murcia

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Joint Diseases.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 15, 2022

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Sponsor : Evonik Operations GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Under the terms of the agreement Nuvothera has acquired an option to exclusively licence rights to develop and commercialise EPADILIN® in the United States.

                          Product Name : Epadilin

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          March 18, 2021

                          Lead Product(s) : Omega-3,Omega 6

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Nuvothera

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Acasti Pharma plans to seek FDA guidance prior to unblinding TRILOGY 2 data, which is expected to delay reporting of TRILOGY 2 topline results until calendar Q3, 2020.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          February 10, 2020

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Akershus University Hospital

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Akershus University Hospital

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dementia.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          April 24, 2019

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : BASF | Pre Diagnostics AS

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Université de Sherbrooke

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Université de Sherbrooke

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          April 01, 2019

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Samuel Fortin, SFC pharma and associate professor UQAR

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Universitaire Ziekenhuizen KU Leuven

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Universitaire Ziekenhuizen KU Leuven

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcopenia.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          August 28, 2018

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Sponsor : KU Leuven | VISTA-Life | Nestle Health Sciences SA

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Nature's Way Canada

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Nature's Way Canada

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          August 29, 2017

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Centre for Contact Lens Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank